Published in Gene Ther on September 01, 2004
Gene therapy with an improved doxycycline-regulated plasmid encoding a tumour necrosis factor-alpha inhibitor in experimental arthritis. Arthritis Res Ther (2007) 0.85
Polymer-mediated DNA vaccine delivery via bystander cells requires a proper balance between transfection efficiency and cytotoxicity. J Control Release (2011) 0.83
Transgene expression and local tissue distribution of naked and polymer-condensed plasmid DNA after intradermal administration in mice. J Control Release (2012) 0.77
Effects of APC De-targeting and GAr modification on the duration of luciferase expression from plasmid DNA delivered to skeletal muscle. Curr Gene Ther (2015) 0.77
Polymeric Materials for Gene Delivery and DNA Vaccination. Adv Mater (2008) 0.76
miRNA-mediated silencing in hepatocytes can increase adaptive immune responses to adenovirus vector-delivered transgenic antigens. Mol Ther (2011) 0.76
Schwann cells promote post-traumatic nerve inflammation and neuropathic pain through MHC class II. Sci Rep (2017) 0.75
Identification of a cellular transcription factor involved in E1A trans-activation. Cell (1986) 6.36
Role of an adenovirus E2 promoter binding factor in E1A-mediated coordinate gene control. Proc Natl Acad Sci U S A (1987) 4.68
The coxsackievirus-adenovirus receptor protein can function as a cellular attachment protein for adenovirus serotypes from subgroups A, C, D, E, and F. J Virol (1998) 4.26
Clonal isolation of muscle-derived cells capable of enhancing muscle regeneration and bone healing. J Cell Biol (2000) 2.75
Adenovirus targeted to heparan-containing receptors increases its gene delivery efficiency to multiple cell types. Nat Biotechnol (1996) 2.69
Increased in vitro and in vivo gene transfer by adenovirus vectors containing chimeric fiber proteins. J Virol (1997) 2.64
Development of approaches to improve cell survival in myoblast transfer therapy. J Cell Biol (1998) 2.57
Identification of a conserved receptor-binding site on the fiber proteins of CAR-recognizing adenoviridae. Science (1999) 2.56
E1A transcription induction: enhanced binding of a factor to upstream promoter sequences. Science (1986) 2.49
Promoter interaction of the E1A-inducible factor E2F and its potential role in the formation of a multi-component complex. EMBO J (1987) 2.30
Developmental control of a promoter-specific factor that is also regulated by the E1A gene product. Cell (1987) 2.29
Activation of a preexisting cellular factor as a basis for adenovirus E1A-mediated transcription control. Proc Natl Acad Sci U S A (1988) 2.16
Targeting of adenovirus penton base to new receptors through replacement of its RGD motif with other receptor-specific peptide motifs. Gene Ther (1995) 1.87
Targeted adenovirus gene transfer to endothelial and smooth muscle cells by using bispecific antibodies. J Virol (1996) 1.85
Reversal of impaired wound repair in iNOS-deficient mice by topical adenoviral-mediated iNOS gene transfer. J Clin Invest (1998) 1.85
A gene transfer vector-cell line system for complete functional complementation of adenovirus early regions E1 and E4. J Virol (1996) 1.84
Expression of the E2F1 transcription factor overcomes type beta transforming growth factor-mediated growth suppression. Proc Natl Acad Sci U S A (1995) 1.81
Results of a triple blind clinical study of myoblast transplantations without immunosuppressive treatment in young boys with Duchenne muscular dystrophy. Cell Transplant (1994) 1.78
Adenovirus infection stimulates the Raf/MAPK signaling pathway and induces interleukin-8 expression. J Virol (1997) 1.78
Emergence of early region 1-containing replication-competent adenovirus in stocks of replication-defective adenovirus recombinants (delta E1 + delta E3) during multiple passages in 293 cells. Hum Gene Ther (1994) 1.74
"Sero-switch" adenovirus-mediated in vivo gene transfer: circumvention of anti-adenovirus humoral immune defenses against repeat adenovirus vector administration by changing the adenovirus serotype. Hum Gene Ther (1996) 1.70
Reducing the native tropism of adenovirus vectors requires removal of both CAR and integrin interactions. J Virol (2001) 1.66
Identification of contact residues and definition of the CAR-binding site of adenovirus type 5 fiber protein. J Virol (2000) 1.65
Muscle-derived stem cells. Gene Ther (2002) 1.60
Circumvention of anti-adenovirus neutralizing immunity by administration of an adenoviral vector of an alternate serotype. Hum Gene Ther (1997) 1.59
Growth factors improve muscle healing in vivo. J Bone Joint Surg Br (2000) 1.57
Airway epithelial CFTR mRNA expression in cystic fibrosis patients after repetitive administration of a recombinant adenovirus. J Clin Invest (1999) 1.56
CAR-dependent and CAR-independent pathways of adenovirus vector-mediated gene transfer and expression in human fibroblasts. J Clin Invest (1999) 1.55
The adenovirus E4 gene, in addition to the E1A gene, is important for trans-activation of E2 transcription and for E2F activation. J Virol (1989) 1.50
The use of an antifibrosis agent to improve muscle recovery after laceration. Am J Sports Med (2001) 1.46
1-year follow-up of autologous muscle-derived stem cell injection pilot study to treat stress urinary incontinence. Int Urogynecol J Pelvic Floor Dysfunct (2008) 1.45
Long-term self-renewal of postnatal muscle-derived stem cells. Mol Biol Cell (2005) 1.42
Flow cytometric characterization of myogenic cell populations obtained via the preplate technique: potential for rapid isolation of muscle-derived stem cells. Hum Gene Ther (2001) 1.42
Efficient inhibition of intimal hyperplasia by adenovirus-mediated inducible nitric oxide synthase gene transfer to rats and pigs in vivo. J Am Coll Surg (1998) 1.38
Mutations in the DG loop of adenovirus type 5 fiber knob protein abolish high-affinity binding to its cellular receptor CAR. J Virol (1999) 1.37
Biologic bypass with the use of adenovirus-mediated gene transfer of the complementary deoxyribonucleic acid for vascular endothelial growth factor 121 improves myocardial perfusion and function in the ischemic porcine heart. J Thorac Cardiovasc Surg (1998) 1.37
Attenuation of mild hyperandrogenic activity in postpubertal acne by a triphasic oral contraceptive containing low doses of ethynyl estradiol and d,l-norgestrel. J Clin Endocrinol Metab (1990) 1.37
The effects of periurethral muscle-derived stem cell injection on leak point pressure in a rat model of stress urinary incontinence. Int Urogynecol J Pelvic Floor Dysfunct (2003) 1.32
RelA is a potent transcriptional activator of the CD28 response element within the interleukin 2 promoter. Mol Cell Biol (1995) 1.29
First genome-wide association scan on neurophysiological endophenotypes points to trans-regulation effects on SLC2A3 in dyslexic children. Mol Psychiatry (2009) 1.27
A requirement for the rac1 GTPase in the signal transduction pathway leading to cardiac myocyte hypertrophy. J Clin Invest (1998) 1.27
Selectivity of a replication-competent adenovirus for human breast carcinoma cells expressing the MUC1 antigen. J Clin Invest (2000) 1.25
Adenoviral transfer of the viral IL-10 gene periarticularly to mouse paws suppresses development of collagen-induced arthritis in both injected and uninjected paws. J Immunol (1999) 1.24
Pseudocyanotic pigmentation of the skin induced by amiodarone: a light and electron microscopic study. Can Med Assoc J (1975) 1.21
Chromosomal localization and nucleoside diphosphate kinase activity of human metastasis-suppressor genes NM23-1 and NM23-2. Oncogene (1993) 1.20
Adenovirus-mediated gene transfer of human inducible nitric oxide synthase in porcine vein grafts inhibits intimal hyperplasia. J Vasc Surg (2001) 1.20
Direct adenoviral gene transfer of viral IL-10 to rabbit knees with experimental arthritis ameliorates disease in both injected and contralateral control knees. J Immunol (1999) 1.19
Muscle-derived stem cells: characterization and potential for cell-mediated therapy. Blood Cells Mol Dis (2002) 1.19
Regional suppression of tumor growth by in vivo transfer of a cDNA encoding a secreted form of the extracellular domain of the flt-1 vascular endothelial growth factor receptor. Hum Gene Ther (1998) 1.19
Suturing versus immobilization of a muscle laceration. A morphological and functional study in a mouse model. Am J Sports Med (1999) 1.19
Efficient activation of viral genomes by levels of herpes simplex virus ICP0 insufficient to affect cellular gene expression or cell survival. J Virol (2001) 1.17
Activation of transgene expression by early region 4 is responsible for a high level of persistent transgene expression from adenovirus vectors in vivo. J Virol (1997) 1.17
A factor discriminating between the wild-type and a mutant polyomavirus enhancer. Nature (1987) 1.16
Adenovirus-mediated direct gene therapy with bone morphogenetic protein-2 produces bone. Bone (1999) 1.16
Effect of bone morphogenetic protein-2-expressing muscle-derived cells on healing of critical-sized bone defects in mice. J Bone Joint Surg Am (2001) 1.15
Dystrophin expression in muscles of mdx mice after adenovirus-mediated in vivo gene transfer. Hum Gene Ther (1996) 1.14
Adenoviral transfer of the inducible nitric oxide synthase gene blocks endothelial cell apoptosis. Surgery (1997) 1.14
The use of adeno-associated virus to circumvent the maturation-dependent viral transduction of muscle fibers. Hum Gene Ther (2000) 1.14
New use of a three-dimensional pellet culture system for human intervertebral disc cells: initial characterization and potential use for tissue engineering. Spine (Phila Pa 1976) (2001) 1.14
Interaction of the adenovirus 14.7-kDa protein with FLICE inhibits Fas ligand-induced apoptosis. J Biol Chem (1998) 1.13
Adenovirus type 9 fiber knob binds to the coxsackie B virus-adenovirus receptor (CAR) with lower affinity than fiber knobs of other CAR-binding adenovirus serotypes. J Virol (2001) 1.13
Review: gene- and stem cell-based therapeutics for bone regeneration and repair. Tissue Eng (2007) 1.12
Inhibition of angiogenesis by adenovirus-mediated sFlt-1 expression in a rat model of corneal neovascularization. Hum Gene Ther (2001) 1.11
Analysis of rabbit articular cartilage repair after chondrocyte implantation using optical coherence tomography. Osteoarthritis Cartilage (2003) 1.11
Mechanisms of muscle stem cell expansion with cytokines. Stem Cells (2002) 1.10
Use of growth factors to improve muscle healing after strain injury. Clin Orthop Relat Res (2000) 1.10
Regeneration of dystrophin-expressing myocytes in the mdx heart by skeletal muscle stem cells. Gene Ther (2005) 1.10
Targeted adenovirus-mediated gene delivery to T cells via CD3. J Virol (1997) 1.09
Construction of a pseudoreceptor that mediates transduction by adenoviruses expressing a ligand in fiber or penton base. J Virol (1999) 1.08
VEGF stimulates MAPK through a pathway that is unique for receptor tyrosine kinases. Biochem Biophys Res Commun (1999) 1.08
Preliminary results of myoblast injection into the urethra and bladder wall: a possible method for the treatment of stress urinary incontinence and impaired detrusor contractility. Neurourol Urodyn (2000) 1.07
Modeling stem cell population growth: incorporating terms for proliferative heterogeneity. Stem Cells (2003) 1.06
Protection from reoxygenation injury by inhibition of rac1. J Clin Invest (1998) 1.05
Ex vivo gene therapy to produce bone using different cell types. Clin Orthop Relat Res (2000) 1.04
Inducible nitric oxide synthase suppresses the development of allograft arteriosclerosis. J Clin Invest (1997) 1.04
Cultured human myoblasts and myotubes show markedly different transducibility by replication-defective adenovirus recombinants. Gene Ther (1994) 1.03
The effect of platelet-rich plasma on the regenerative therapy of muscle derived stem cells for articular cartilage repair. Osteoarthritis Cartilage (2012) 1.02
The Pittsburgh Tissue Engineering Initiative. Clin Plast Surg (1999) 1.01
Adenovirus-mediated inducible nitric oxide synthase gene transfer inhibits hepatocyte apoptosis. Surgery (1998) 1.00
Inhibition of the IKK/NF-κB pathway by AAV gene transfer improves muscle regeneration in older mdx mice. Gene Ther (2010) 1.00
Matching host muscle and donor myoblasts for myosin heavy chain improves myoblast transfer therapy. Gene Ther (2000) 0.99
Development of approaches to improve the healing following muscle contusion. Cell Transplant (1999) 0.98
Muscle injuries and repair: the role of prostaglandins and inflammation. Histol Histopathol (2003) 0.98
Myoblast therapy for stress urinary incontinence and bladder dysfunction. World J Urol (2000) 0.97
Human skeletal muscle cells in ex vivo gene therapy to deliver bone morphogenetic protein-2. J Bone Joint Surg Br (2002) 0.97
An inhibitory mutant of c-Raf-1 blocks v-Src-induced activation of the Egr-1 promoter. J Biol Chem (1991) 0.96
Adenovirus-mediated VEGF(121) gene transfer stimulates angiogenesis in normoperfused skeletal muscle and preserves tissue perfusion after induction of ischemia. Circulation (2000) 0.95
Viral gene delivery to skeletal muscle: insights on maturation-dependent loss of fiber infectivity for adenovirus and herpes simplex type 1 viral vectors. Hum Gene Ther (1997) 0.94
The role of receptors in the maturation-dependent adenoviral transduction of myofibers. Gene Ther (2001) 0.94
Limb lengthening promotes muscle growth. J Orthop Res (1997) 0.94
Induction of antitumor immunity by direct intratumoral injection of a recombinant adenovirus vector expressing interleukin-12. Cancer Gene Ther (1999) 0.94
Effective repeat administration with adenovirus vectors to the muscle. Gene Ther (2000) 0.93
Expression of major histocompatibility complex antigens on human myoblasts. Transplant Proc (1991) 0.92
The HIV-1 nef protein does not have guanine nucleotide binding, GTPase, or autophosphorylating activities. AIDS Res Hum Retroviruses (1991) 0.92
Ex vivo gene transfer using adenovirus-mediated full-length dystrophin delivery to dystrophic muscles. Gene Ther (1998) 0.92
Persistence and survival of autologous muscle derived cells versus bovine collagen as potential treatment of stress urinary incontinence. J Urol (2001) 0.91
Transactivation by the adenovirus E1A gene. Biochem Cell Biol (1988) 0.91